Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial

Table 2 Duration of therapy (MITT, early switch subpopulation, late switch subpopulation, and no switch subpopulation)

	MITT population			Early switch subpopulation			Late switch subpopulation			No switch subpopulation
	(n = 250)			(n = 102)			(n = 48)			(n = 100)
	n (%)	Median, days	Range, days	n (%)	Median, days	Range, days	n (%)	Median, days	Range, days	n (%)	Median, days	Range, days
Duration of overall therapy (IV + oral)	250 (100)	14.0	1-56	102 (100)	14.0	5-56	48 (100)	19.0	8-42	100 (100)	12.0	1-29
Duration of IV anidulafungin portion of therapy*	250 (100)	6.0	1-29	102 (100)	5.0*	1-6*	48 (100)	10.0	6-27	100 (100)	12.0	1-29
Study day of step-down to oral therapy	150 (60)	6.0	1-28	102 (100)	6.0	1-7	48 (100)	11.0	8-28	-	-	-
1-5	7 (4.7)	-	-	7 (6.9)	-	-	-	-	-	-	-	-
6	77 (51.3)	-	-	77 (75.5)	-	-	-	-	-	-	-	-
7	18 (12.0)	-	-	18 (17.6)	-	-	-	-	-	-	-	-
8-14	38 (25.3)	-	-	-	-	-	38 (79.2)	-	-	-	-	-
15-21	6 (4.0)	-	-	-	-	-	6 (12.5)	-	-	-	-	-
22-28	4 (2.7)	-	-	-	-	-	4 (8.3)	-	-	-	-	-

*Represents the duration of IV therapy prior to oral step-down. Four patients from the early switch subpopulation had to be stepped back to IV therapy after initially stepping down to oral azole as they later became unable to tolerate oral medication. Total duration of IV therapy for these patients is, therefore, longer than reported here.
Abbreviations used: IV, intravenous; MITT, modified intent-to-treat.

ISSN: 1471-2334